199 related articles for article (PubMed ID: 38172718)
1. IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients.
Crucitta S; Pasqualetti F; Gonnelli A; Ruglioni M; Luculli GI; Cantarella M; Ortenzi V; Scatena C; Paiar F; Naccarato AG; Danesi R; Del Re M
BMC Cancer; 2024 Jan; 24(1):31. PubMed ID: 38172718
[TBL] [Abstract][Full Text] [Related]
2. Detection of IDH1 Mutation in cfDNA and Tissue of Adult Diffuse Glioma with Allele-Specific qPCR.
Husain A; Mishra S; Siddiqui MH; Husain N
Asian Pac J Cancer Prev; 2023 Mar; 24(3):961-968. PubMed ID: 36974551
[TBL] [Abstract][Full Text] [Related]
3. Detection of IDH1 mutation in the plasma of patients with glioma.
Boisselier B; Gállego Pérez-Larraya J; Rossetto M; Labussière M; Ciccarino P; Marie Y; Delattre JY; Sanson M
Neurology; 2012 Oct; 79(16):1693-8. PubMed ID: 23035067
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
5. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T
Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355
[TBL] [Abstract][Full Text] [Related]
6. Minimally Invasive Detection of IDH1 Mutation With Cell-Free Circulating Tumor DNA and D-2-Hydroxyglutarate, D/L-2-Hydroxyglutarate Ratio in Gliomas.
Tuna G; Dal-Bekar NE; Akay A; Rükşen M; İşlekel S; İşlekel GH
J Neuropathol Exp Neurol; 2022 Jun; 81(7):502-510. PubMed ID: 35582888
[TBL] [Abstract][Full Text] [Related]
7. A novel COLD-PCR/FMCA assay enhances the detection of low-abundance IDH1 mutations in gliomas.
Pang B; Durso MB; Hamilton RL; Nikiforova MN
Diagn Mol Pathol; 2013 Mar; 22(1):28-34. PubMed ID: 23370430
[TBL] [Abstract][Full Text] [Related]
8. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
[TBL] [Abstract][Full Text] [Related]
10. IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy.
Neal A; Kwan P; O'Brien TJ; Buckland ME; Gonzales M; Morokoff A
Epilepsy Behav; 2018 Jan; 78():30-36. PubMed ID: 29172136
[TBL] [Abstract][Full Text] [Related]
11. An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.
Lewandowska MA; Furtak J; Szylberg T; Roszkowski K; Windorbska W; Rytlewska J; Jóźwicki W
Mol Diagn Ther; 2014 Feb; 18(1):45-53. PubMed ID: 23934769
[TBL] [Abstract][Full Text] [Related]
12. A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR.
Hirano M; Ohka F; Maeda S; Chalise L; Yamamichi A; Aoki K; Kato A; Tanahashi K; Motomura K; Nishimura Y; Hara M; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
Brain Tumor Pathol; 2018 Apr; 35(2):97-105. PubMed ID: 29460200
[TBL] [Abstract][Full Text] [Related]
13. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.
Zeng A; Hu Q; Liu Y; Wang Z; Cui X; Li R; Yan W; You Y
Oncotarget; 2015 Oct; 6(30):30232-8. PubMed ID: 26338964
[TBL] [Abstract][Full Text] [Related]
14. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
[TBL] [Abstract][Full Text] [Related]
15. Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas.
Cai J; Zhu P; Zhang C; Li Q; Wang Z; Li G; Wang G; Yang P; Li J; Han B; Jiang C; Sun Y; Jiang T
Oncotarget; 2016 Mar; 7(13):16384-95. PubMed ID: 26918938
[TBL] [Abstract][Full Text] [Related]
16. Plasma ctDNA liquid biopsy of IDH1, TERTp, and EGFRvIII mutations in glioma.
Jones JJ; Nguyen H; Wong SQ; Whittle J; Iaria J; Stylli S; Towner J; Pieters T; Gaillard F; Kaye AH; Drummond KJ; Morokoff AP
Neurooncol Adv; 2024; 6(1):vdae027. PubMed ID: 38572065
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation.
Wang YY; Wang K; Li SW; Wang JF; Ma J; Jiang T; Dai JP
AJNR Am J Neuroradiol; 2015 Nov; 36(11):2023-9. PubMed ID: 26316565
[TBL] [Abstract][Full Text] [Related]
18. A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma.
Catteau A; Girardi H; Monville F; Poggionovo C; Carpentier S; Frayssinet V; Voss J; Jenkins R; Boisselier B; Mokhtari K; Sanson M; Peyro-Saint-Paul H; Giannini C
Acta Neuropathol Commun; 2014 Jun; 2():58. PubMed ID: 24889502
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
Poetsch L; Bronnimann C; Loiseau H; Frénel JS; Siegfried A; Seizeur R; Gauchotte G; Cappellen D; Carpentier C; Figarella-Branger D; Eimer S; Meyronet D; Ducray F;
J Neurooncol; 2021 Jan; 151(2):279-286. PubMed ID: 33205355
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas.
Kim D; Kim S; Kim SH; Chang JH; Yun M
Clin Nucl Med; 2018 May; 43(5):311-316. PubMed ID: 29485450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
